Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Emtricitabine: a novel nucleoside reverse transcriptase inhibitor.

Jean-Michel Molina¹, Sandra L Cox

¹Hôpital Sant-Louis, Paris, France.

Drugs of Today (Barcelona, Spain : 1998)

|July 22, 2005

Summary

Emtricitabine, a nucleoside reverse transcriptase inhibitor (NRTI), effectively treats HIV-1 and is being studied for Hepatitis B. Its favorable pharmacokinetics allow once-daily dosing, offering a convenient and well-tolerated HIV treatment option.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Analysis of Viral Blips Through Week 192 of the DRIVE-FORWARD and DRIVE-AHEAD Phase 3 Studies of Doravirine-Based Regimens in Adults Living With Previously Untreated HIV-1.

Open forum infectious diseases·2026

Same author

Revisiting gonorrhoea prevention in the era of resistance and biomedical interventions.

Sexually transmitted infections·2026

Same author

Knowledge, attitudes and behaviours in relation to doxycycline post-exposure prophylaxis use among attendees and healthcare workers at two sexual health services in Ireland.

Sexually transmitted infections·2026

Same author

Safety and Tolerability of Oral Islatravir Once Monthly as Pre-Exposure Prophylaxis in Cisgender Men and Transgender Women Who Have an Elevated Likelihood of HIV-1 Exposure: Results From the IMPOWER-24 Randomized Phase 3 Study.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026

Same author

Fixed-dose daily doravirine (100 mg) with islatravir (0·25 mg) versus bictegravir, emtricitabine, and tenofovir alafenamide for initial HIV-1 therapy: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trial.

The lancet. HIV·2026

Same author

Doravirine versus dolutegravir-based regimen in antiretroviral treatment-naive people living with HIV-1 (ANRS0392s ELDORADO): protocol for an international, open-label, randomised, non-inferiority, phase III trial.

BMJ open·2026

Area of Science:

Pharmacology
Virology
Infectious Diseases

Background:

Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) used to treat HIV-1.
It is also under investigation for treating hepatitis B virus (HBV) infection.

Purpose of the Study:

To evaluate the efficacy and pharmacokinetic profile of emtricitabine in HIV-1 treatment.
To assess its effectiveness in combination therapy for HIV-1 and its potential in HBV treatment.

Main Methods:

Emtricitabine is administered as a once-daily 200-mg capsule.
Its antiviral effect is mediated by its triphosphate derivative, which causes DNA chain termination.
Clinical trials compared emtricitabine-based regimens to other antiretroviral therapies.

Related Experiment Videos

Main Results:

Emtricitabine exhibits a favorable pharmacokinetic profile with a long plasma elimination half-life (8-10 hours) and intracellular half-life (39 hours).
Once-daily emtricitabine is effective in suppressing HIV-1 RNA in adults and children when used in triple-drug regimens.
It demonstrates comparable efficacy to protease inhibitor-based regimens and is effective against HBV in co-infected and mono-infected patients.

Conclusions:

Emtricitabine is a well-tolerated, effective NRTI for HIV-1 treatment with a convenient once-daily dosing schedule.
Its combination with tenofovir offers an attractive backbone for antiretroviral therapy.
Emtricitabine shows promise for treating HBV infection.